Alexander Loftus MD , Richard Hoehn MD , Timothy Nywening MD, MS, MPHS
{"title":"细胞减少和HIPEC在结直肠癌中的作用","authors":"Alexander Loftus MD , Richard Hoehn MD , Timothy Nywening MD, MS, MPHS","doi":"10.1016/j.scrs.2023.100970","DOIUrl":null,"url":null,"abstract":"<div><p><span>Peritoneal metastases<span> from colorectal cancer have a dismal natural history and poor response to systemic chemotherapy. Cytoreductive surgery<span>, the mainstay of locoregional control of peritoneal carcinomatosis<span>, with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown survival benefit in selected patients. While recent studies such as the PRODIGE 7 trial have not demonstrated added benefit of HIPEC, these trials have limitations (i.e. choice of HIPEC agent, patient population), and more studies are needed. The efficacy of prophylactic HIPEC </span></span></span></span>in patients at high risk for peritoneal recurrence remains controversial. Ongoing trials, including intraperitoneal delivery of novel anti-cancer agents, may yield significant new therapeutic options.</p></div>","PeriodicalId":55956,"journal":{"name":"Seminars in Colon and Rectal Surgery","volume":"34 3","pages":"Article 100970"},"PeriodicalIF":0.4000,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evolving role of cytoreduction and HIPEC for colorectal cancer\",\"authors\":\"Alexander Loftus MD , Richard Hoehn MD , Timothy Nywening MD, MS, MPHS\",\"doi\":\"10.1016/j.scrs.2023.100970\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span>Peritoneal metastases<span> from colorectal cancer have a dismal natural history and poor response to systemic chemotherapy. Cytoreductive surgery<span>, the mainstay of locoregional control of peritoneal carcinomatosis<span>, with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown survival benefit in selected patients. While recent studies such as the PRODIGE 7 trial have not demonstrated added benefit of HIPEC, these trials have limitations (i.e. choice of HIPEC agent, patient population), and more studies are needed. The efficacy of prophylactic HIPEC </span></span></span></span>in patients at high risk for peritoneal recurrence remains controversial. Ongoing trials, including intraperitoneal delivery of novel anti-cancer agents, may yield significant new therapeutic options.</p></div>\",\"PeriodicalId\":55956,\"journal\":{\"name\":\"Seminars in Colon and Rectal Surgery\",\"volume\":\"34 3\",\"pages\":\"Article 100970\"},\"PeriodicalIF\":0.4000,\"publicationDate\":\"2023-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Seminars in Colon and Rectal Surgery\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1043148923000301\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"SURGERY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Seminars in Colon and Rectal Surgery","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1043148923000301","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"SURGERY","Score":null,"Total":0}
Evolving role of cytoreduction and HIPEC for colorectal cancer
Peritoneal metastases from colorectal cancer have a dismal natural history and poor response to systemic chemotherapy. Cytoreductive surgery, the mainstay of locoregional control of peritoneal carcinomatosis, with hyperthermic intraperitoneal chemotherapy (HIPEC) has shown survival benefit in selected patients. While recent studies such as the PRODIGE 7 trial have not demonstrated added benefit of HIPEC, these trials have limitations (i.e. choice of HIPEC agent, patient population), and more studies are needed. The efficacy of prophylactic HIPEC in patients at high risk for peritoneal recurrence remains controversial. Ongoing trials, including intraperitoneal delivery of novel anti-cancer agents, may yield significant new therapeutic options.
期刊介绍：
Seminars in Colon and Rectal Surgery offers a comprehensive and coordinated review of a single, timely topic related to the diagnosis and treatment of proctologic diseases. Each issue is an organized compendium of practical information that serves as a lasting reference for colorectal surgeons, general surgeons, surgeons in training and their colleagues in medicine with an interest in colorectal disorders.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
